Inferring tumour purity and stromal and immune cell admixture from expression data
Open Access
- 11 October 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 4 (1), 2612
- https://doi.org/10.1038/ncomms3612
Abstract
Infiltrating stromal and immune cells form the major fraction of normal cells in tumour tissue and not only perturb the tumour signal in molecular studies but also have an important role in cancer biology. Here we describe ‘Estimation of STromal and Immune cells in MAlignant Tumours using Expression data’ (ESTIMATE)—a method that uses gene expression signatures to infer the fraction of stromal and immune cells in tumour samples. ESTIMATE scores correlate with DNA copy number-based tumour purity across samples from 11 different tumour types, profiled on Agilent, Affymetrix platforms or based on RNA sequencing and available through The Cancer Genome Atlas. The prediction accuracy is further corroborated using 3,809 transcriptional profiles available elsewhere in the public domain. The ESTIMATE method allows consideration of tumour-associated normal cells in genomic and transcriptomic studies. An R-library is available on https://sourceforge.net/projects/estimateproject/.This publication has 60 references indexed in Scilit:
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Comprehensive genomic characterization of squamous cell lung cancersNature, 2012
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretionNature, 2012
- The Life History of 21 Breast CancersCell, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Immunity, Inflammation, and CancerCell, 2010
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1Nature, 2009
- Terminal Differentiation of Human Breast Cancer through PPARγMolecular Cell, 1998